The Business Times
SUBSCRIBERS

‘A GPS for stem cells’: TargaZyme’s Singapore CEO wants to cure cancer

The company aims to develop cancer immunotherapies using its cell efficacy multiplier technology.

Summarise
Megan Cheah

Megan Cheah

Published Tue, May 27, 2025 · 07:00 AM
    • Increasing the safety profile of the stem cells is also important to TargaZyme’s multiplier technology, which is infused into patients as a drug.
    • Increasing the safety profile of the stem cells is also important to TargaZyme’s multiplier technology, which is infused into patients as a drug. PHOTO: PIXABAY

    [SINGAPORE] After watching her family members go through painful treatment methods to deal with their cancer diagnoses, Lynnet Koh turned to cell therapy to find new ways to cure the debilitating disease.

    “Unlike other areas in medicine, which primarily treat side effects of the disease and extend life by a few months, I really wanted to cure patients without all the toxic side effects,” she said.

    Koh is bullish on the potential of stem cells, which has a growing market. Research house Grandview Research placed the global stem cell market at US$15.1 billion in 2024 and is expected to grow at a compound annual growth rate of 11.4 per cent from 2025 to 2030.

    stem cellHealthcare

    Copyright SPH Media. All rights reserved.

    Reuse this contentFeedback
    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More